---
title: "Metabolic Fatty Liver Disease (MAFLD): Causes, Symptoms, and Natural Treatments"
entity: "blog"
canonical_url: "https://www.drdanwool.com/blog/metabolic-fatty-liver-disease"
markdown_url: "https://www.drdanwool.com/llms/blog/metabolic-fatty-liver-disease"
lastmod: "2026-06-11T07:02:00.000Z"
---

[Home](/Home) > [Articles](https://drdanwool.com/blog) > [Metabolic Fatty Liver Disease](https://drdanwool.com/blog/metabolic-fatty-liver-disease)

Medically reviewed by [Dr. Dan Wool, NMD](https://www.linkedin.com/in/drdanwool/)

 Arizona-licensed Naturopathic Physician and  Gastroenterology Specialist

 Updated: June 11, 2026

Quick Summary:

- MAFLD (formerly NAFLD) is the most common chronic liver disease worldwide, affecting roughly 1 in 3 adults globally and closely tied to obesity, insulin resistance, and metabolic syndrome.
- Most people have no symptoms until the disease progresses; routine blood work or imaging often catches it first, making regular metabolic screening essential.
- Lifestyle change — especially weight loss, the Mediterranean diet, and regular exercise — remains the most effective first-line treatment supported by clinical evidence.
- Natural therapies including omega-3 fatty acids, vitamin E, milk thistle, and berberine show meaningful promise in research for reducing liver fat and inflammation.

## Overview

If your doctor has ever mentioned fatty liver disease — or if you have been told your liver enzymes are elevated — you are not alone. Metabolic fatty liver disease affects an estimated one-third of adults worldwide, and most people do not know they have it. The good news is that, caught early, this condition is largely reversible with the right approach. This article explains what MAFLD is, why it matters, and what you can do about it — including natural options that are backed by growing clinical evidence.

## What Is Metabolic Fatty Liver Disease (MAFLD)?

Metabolic fatty liver disease — formerly called non-alcoholic fatty liver disease (NAFLD) — is a condition in which excess fat builds up inside liver cells due to metabolic dysfunction, not alcohol use. The name was formally updated in 2020 by an international panel of experts to better reflect the true root cause of the disease: disrupted metabolism.

MAFLD exists on a spectrum. At the mild end is simple hepatic steatosis, where fat accumulates in the liver with little or no damage. As the disease progresses, it can develop into metabolic-associated steatohepatitis (MASH) — an inflammatory state that can lead to liver scarring (fibrosis), cirrhosis, and in severe cases, liver cancer (hepatocellular carcinoma).

To receive a diagnosis of MAFLD, a person must have evidence of fat in the liver (at least 5% of liver cells affected) plus at least one of the following: overweight or obesity, type 2 diabetes, or signs of metabolic dysfunction such as high blood pressure, elevated triglycerides, or insulin resistance. Unlike the old NAFLD definition, MAFLD is a positive diagnosis based on what is present — not a process of ruling everything else out.

Global prevalence has risen from about 22% in 1991 to over 37% in 2019, and the upward trend continues alongside rising rates of obesity and type 2 diabetes.

## What Are the Symptoms of MAFLD?

This is where MAFLD earns its nickname as a "silent" disease. Most people have no obvious symptoms during the early stages. When symptoms do appear, they tend to be vague and easy to dismiss. Common signs include:

Fatigue that does not improve with rest. A dull ache or sense of fullness in the upper right abdomen, where the liver sits. [Elevated liver enzymes (AST, ALT)](/blog/liver-enzymes)found on routine blood work. Evidence of liver fat on an ultrasound, CT scan, or MRI performed for another reason.

If MAFLD progresses to cirrhosis, more serious symptoms emerge: fluid buildup in the abdomen, easy bruising, yellowing of the skin or eyes (jaundice), and mental confusion. At that stage, the damage is much harder to reverse.

Because most people have no early warning signs, routine metabolic screening is one of the most important tools for catching MAFLD before significant damage occurs.

## Important Considerations for MAFLD — Including Who Should Be Cautious

MAFLD does not exist in isolation. People with this condition carry a significantly elevated risk of cardiovascular disease, which remains the leading cause of death in this population — ahead of liver-related complications. Kidney disease is also more common in people with MAFLD compared to those without it.

Certain groups face higher risk and deserve extra vigilance. People with type 2 diabetes have MAFLD prevalence rates approaching 60 to 70%. Those with obesity (BMI over 30), metabolic syndrome, sleep apnea, polycystic ovary syndrome (PCOS), or hypothyroidism are also at elevated risk. Genetic factors — particularly variants in the PNPLA3 and TM6SF2 genes — can increase susceptibility even in people who are lean.

Important clinical cautions: If you already have cirrhosis (advanced scarring), many supplements and herbal therapies may place additional stress on a compromised liver and should only be used under direct medical supervision. Alcohol — even in moderate amounts — acts as a synergistic toxin in MAFLD and worsens disease progression. Many common over-the-counter medications, including high-dose acetaminophen (Tylenol) and certain statins, can further stress a fatty liver. Always disclose all supplements and medications to your provider.

## What Research Says About MAFLD

The scientific literature on MAFLD has expanded rapidly. Several findings stand out as especially relevant for patients exploring naturopathic and integrative options.

- Lifestyle as medicine: European clinical practice guidelines from EASL, EASD, and EASO (2024) confirm that lifestyle modification — including weight reduction, Mediterranean diet adherence, and regular exercise — remains the cornerstone of MAFLD treatment. A weight loss of just 5 to 10% of body weight can produce meaningful reductions in liver fat. Losing more than 10% has been shown to improve or even reverse liver fibrosis in some patients.

- Mediterranean diet evidence: A randomized controlled trial published in 2025 found that both a Mediterranean diet and a low-fat diet produced similar reductions in liver fat and stiffness over 12 weeks, with weight loss being the key driver. A separate 2024 review confirmed that higher adherence to the Mediterranean dietary pattern is associated with lower rates of MAFLD and slower fibrosis progression.

- Exercise: Combining aerobic exercise with resistance (strength) training is more effective at reducing liver fat than either approach alone. Even without weight loss, regular exercise improves insulin sensitivity and reduces liver inflammation.

- Pharmacological options: GLP-1 receptor agonist therapies — including semaglutide and tirzepatide — are increasingly recognized in guidelines as useful tools in MAFLD management for patients who also have obesity or type 2 diabetes. Resmetirom (a thyroid hormone receptor agonist) received FDA approval in 2024 specifically for MASH with significant fibrosis, marking the first approved MASH-targeted therapy.

## What to Expect When Addressing MAFLD

Managing MAFLD is not a quick fix — it is a sustained lifestyle effort. Here is what a realistic trajectory looks like:

In the first few months, dietary changes and a structured exercise program are introduced. Blood work (liver enzymes, fasting glucose, lipid panel) is repeated at 8-12 weeks to assess response. Imaging (FibroScan or ultrasound elastography) is typically repeated at 6-12 months to evaluate changes in liver fat and stiffness.

Patients who achieve consistent weight loss and maintain dietary changes can often normalize liver enzymes within 3 to 6 months. Reversal of early fibrosis may require 12-24 months of sustained effort. Without intervention, however, roughly 20% of people with MASH will develop significant fibrosis within 4 years.

A naturopathic approach integrates these timelines with personalized support for adherence: meal planning, stress management, sleep optimization, and addressing underlying hormonal or metabolic barriers that make lifestyle change harder.

## Natural Alternatives and Integrative Approaches

Several natural therapies have meaningful research support for MAFLD and are commonly used in naturopathic practice:

- Omega-3 fatty acids (EPA/DHA): Evidence supports their use for reducing liver fat (steatosis) and improving triglyceride levels. Typical doses range from 2 to 4 grams per day. Liver biopsy studies show modest improvements in steatosis but mixed results on fibrosis.

- Vitamin E (as alpha-tocopherol): Clinical trials, including the PIVENS trial, found that vitamin E at 800 IU daily reduced liver inflammation and improved liver enzyme levels in non-diabetic adults with MASH. Use with caution in those with prostate cancer risk.

- Milk thistle (silymarin): One of the most studied hepatoprotective botanicals. Silymarin has antioxidant and anti-inflammatory properties shown to reduce liver enzyme levels and support liver cell repair in several clinical trials.

- Berberine: This plant alkaloid improves insulin sensitivity and has been studied specifically for MAFLD in clinical trials. Results show reductions in liver fat, fasting glucose, and liver enzymes. It may also favorably modulate the gut microbiome, which plays a role in MAFLD progression.

- Coffee: Multiple epidemiologic studies associate regular coffee consumption (2 to 3 cups per day) with lower rates of liver fibrosis and cirrhosis. The mechanism appears to involve antioxidant and anti-inflammatory compounds in coffee independent of caffeine.

Intermittent fasting: Time-restricted eating protocols have shown benefit in several small trials for reducing liver fat and improving metabolic markers, though large randomized trials in MAFLD are still needed.

## The Bottom Line on Metabolic Fatty Liver Disease

MAFLD is one of the most common and underdiagnosed conditions in adults today — and one of the most modifiable. Because it rarely causes symptoms early on, many people are unaware they have it until it shows up incidentally on labs or imaging. The window of opportunity to reverse it is widest at the early stages.

The most powerful intervention remains lifestyle change: sustained weight loss, a Mediterranean-style diet, and consistent physical activity. Naturopathic medicine adds a personalized, root-cause layer to this framework — addressing insulin resistance, gut health, hormonal imbalances, and nutritional deficiencies that conventional approaches may overlook.

If you have been told you have elevated liver enzymes, fatty liver on imaging, or metabolic syndrome, a thorough evaluation is the right next step. The liver has remarkable regenerative capacity — but it needs the right support to use it.

## Frequently Asked Questions About Metabolic Fatty Liver Disease (MAFLD)

### Can fatty liver disease be reversed completely?

Quick Answer: Yes - in its early stages, MAFLD can be fully reversed with sustained lifestyle changes, particularly weight loss of 5-10% or more and a healthier diet.

Full Answer: The liver has a strong ability to regenerate, and early-stage MAFLD (simple steatosis or mild MASH without significant fibrosis) is considered largely reversible. Clinical studies show that losing 7-10% of body weight can reduce liver fat substantially. Even early fibrosis (Stage 1-2) may improve with sustained lifestyle intervention. Advanced fibrosis and cirrhosis are harder to reverse and require more aggressive medical management. The sooner intervention begins, the better the outcome.

### Is MAFLD the same as NAFLD? Why did the name change?

Quick Answer: They describe the same condition. NAFLD was renamed MAFLD in 2020 to better reflect the true cause — metabolic dysfunction — and to remove the stigmatizing focus on alcohol.

Full Answer: For decades, the condition was called non-alcoholic fatty liver disease (NAFLD) — a name that defined the disease by what it was not (alcohol-related), rather than what it actually is. In 2020, an international consensus of liver disease experts proposed the term metabolic dysfunction-associated fatty liver disease (MAFLD) to shift focus toward the metabolic roots of the disease: insulin resistance, obesity, and type 2 diabetes. This change also allows the diagnosis to coexist with other liver conditions rather than requiring exclusion of all other causes. The term MASLD (metabolic dysfunction-associated steatotic liver disease) was introduced in 2023 as an additional refinement.

### What foods should I avoid if I have fatty liver disease?

Quick Answer: Avoid added sugars, refined carbohydrates, ultra-processed foods, sugary beverages (including fruit juice), and alcohol — all of which directly drive liver fat accumulation.

Full Answer: Diet is one of the most powerful levers in MAFLD management. Fructose-rich foods — particularly high-fructose corn syrup found in sodas and packaged snacks — are especially harmful because the liver metabolizes fructose directly into fat. Refined carbohydrates (white bread, pastries, white rice) spike blood sugar and insulin, promoting fat storage in the liver. Alcohol, even in moderate amounts, accelerates liver inflammation and fibrosis in MAFLD patients. Research consistently supports a Mediterranean-style diet — rich in olive oil, fish, vegetables, legumes, and whole grains — as the most beneficial dietary pattern for liver health.

### Can you have fatty liver disease if you are not overweight?

Quick Answer: Yes. "Lean MAFLD" affects roughly 10 to 20% of normal-weight individuals and can carry similar risks to MAFLD in those with obesity.

Full Answer: MAFLD is strongly associated with obesity, but it is not exclusive to it. Lean MAFLD — occurring in people with a normal BMI — is a recognized and clinically important variant. These individuals often have underlying insulin resistance, genetic susceptibility (particularly PNPLA3 gene variants), or visceral fat despite a normal overall weight. Research shows that lean MAFLD can carry a similar long-term prognosis to obesity-related MAFLD. This is why metabolic screening, not just BMI measurement, is essential for detecting liver disease risk.

### How is MAFLD diagnosed — what tests are done?

Quick Answer: MAFLD is typically identified through liver enzyme blood tests (AST, ALT), liver imaging (ultrasound or FibroScan), and metabolic lab work. Liver biopsy is reserved for complex or advanced cases.

Full Answer: A typical diagnostic workup begins with liver function tests showing elevated ALT or AST, often found on routine blood work. Abdominal ultrasound can detect fat in the liver (steatosis) but is limited in quantifying fibrosis. FibroScan (transient elastography) is a non-invasive imaging tool that measures both liver fat and stiffness, providing a more precise assessment of fibrosis stage. MRI-PDFF (proton density fat fraction) is the gold standard for quantifying liver fat. A comprehensive metabolic panel, fasting glucose, HbA1c, lipid panel, and sometimes hormone testing help identify underlying metabolic contributors. Liver biopsy is typically reserved for cases where diagnosis is unclear or fibrosis staging is needed to guide treatment decisions.

### Do GLP-1 medications like semaglutide help fatty liver disease?

Quick Answer: Yes. GLP-1 receptor agonists ([semaglutide](/blog/semaglutide), [tirzepatide](/blog/tirzepatide)) have shown clinically meaningful reductions in liver fat and MASH severity in research trials and are included in current treatment guidelines.

Full Answer: [GLP-1](/glp1-peptide-weight-loss) receptor agonists were originally developed for type 2 diabetes and obesity, but their effects on the liver have drawn significant clinical interest. Semaglutide reduced MASH-related inflammation in phase 2 trials, and phase 3 results are expected. Tirzepatide, a dual GIP/GLP-1 agonist, showed robust reductions in liver fat in obesity trials. The 2024 European MASLD guidelines explicitly recommend incretin-based therapies (semaglutide, tirzepatide) as an option for MAFLD patients who also have obesity or type 2 diabetes. These medications work in part by promoting weight loss, reducing insulin resistance, and decreasing hepatic fat synthesis.

## Are You Ready to Fix Your Gut?

Struggling with your gut health? [Dr. Dan Wool](/about) offers personalized, natural solutions at his Scottsdale naturopathic practice.[Book a free 15-minute discovery call today](/booking) and take the first step toward lasting digestive relief.

Disclaimer:

For educational purposes only — not medical advice, diagnosis, treatment or advertising for consumer purchase. Dr. Dan Wool and affiliates make no effectiveness claims about supplements, hormones, peptides or other therapeutics beyond cited clinical evidence and regulatory approval. Always consult a qualified healthcare provider before starting, changing, or stopping any medical or wellness program.

About the Author

## Dr. Dan Wool, NMD

[Dr. Dan Wool](/about) is a naturopathic doctor who specializes in gastroenterology, hormones and men's health in Scottsdale, Arizona. [Set up a free 15-minute discovery call with Dr. Wool today! ](https://drdanwool.com/booking)

[Read more about Dr. Wool's Gut Health Journey](/about)

## References:

1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. [https://doi.org/10.1016/j.jhep.2020.03.039](https://doi.org/10.1016/j.jhep.2020.03.039)

2. Tacke F, Horn P, Wong VWS, et al; EASL, EASD, EASO. Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542. [https://pubmed.ncbi.nlm.nih.gov/38851997/](https://pubmed.ncbi.nlm.nih.gov/38851997/)

3. Chen MJ, Chen Y, Lin JQ, et al. Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease. Front Nutr. 2024;11:1421386. [https://doi.org/10.3389/fnut.2024.1421386](https://doi.org/10.3389/fnut.2024.1421386)

4. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-1556. [https://doi.org/10.1016/j.jhep.2023.06.003](https://doi.org/10.1016/j.jhep.2023.06.003)

5. Perdomo CM, Frühbeck G, Escalada J. Non-pharmacological approach to diet and exercise in metabolic-associated fatty liver disease: bridging the gap between research and clinical practice. Nutrients. 2024;16(3):355. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10817352/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10817352/)

6. Metabolic dysfunction-associated steatotic liver disease (MASLD). StatPearls. National Center for Biotechnology Information. Updated August 2025. [https://www.ncbi.nlm.nih.gov/books/NBK541033/](https://www.ncbi.nlm.nih.gov/books/NBK541033/)

7. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatology International. 2024.[https://link.springer.com/article/10.1007/s12072-024-10704-3](https://link.springer.com/article/10.1007/s12072-024-10704-3)